This week, I had an insightful conversation with David Sans, PhD, FAARM, MBA, who heads healthcare investment banking at EF Hutton. We discussed the intricacies of different Public Offering strategies, including micro IPOs, which offer a unique avenue for biotech companies. David provides a deep perspective on the strategic implications of IPOs for biotech funding. He emphasized the importance of investor support and strategic banking partnerships, especially for micro IPOs. We also discussed the potential of AI in reshaping financial services and the future of outcome-based pricing models in investment. David's personal insights reveal the demanding yet rewarding nature of investment banking and highlight crucial aspects to consider for those pursuing a career in this field. Check out the full episode: https://buildingbiotechspodcast.com/episode/50 ✔️Subscribe to our Mailing List for weekly podcast drops and industry news (we promise no spam!) https://buildingbiotechs.beehiiv.com/ Follow us on Apple, Spotify, or wherever you love to listen. 👉 https://apple.co/3EDuZvA 👉 https://spoti.fi/48bs3nq Stay connected with us: 🌐 Website: https://buildingbiotechspodcast.com/ 💼 LinkedIn: https://www.linkedin.com/company/building-biotechs-podcast/ 🎙️Check out our sister podcast, Biotech Career Coach: https://biotechcareercoach.com/ Follow and Connect with Carina on LinkedIn: https://www.linkedin.com/in/cclingman/ In need of Fractional Talent Acquisition or Recruiting help? Reach out! info@recruitomics.com

This week I had a great conversation with Iva Toudjarska, founder and CEO of Zeal Therapeutics. From earning a PhD in molecular biology to a solid scientific career at Alnylam, to working in venture capital, to selling a successful SaaS company, Iva’s career that’s set her up well to enjoy this new challenge – founding a baby biotech. Her expertise marries business development, venture capital, and company-building. Iva shared valuable advice for biotech founders on securing funding, making strategic decisions, and building effective partnerships. Tune in to hear her experiences, lessons learned, and her current work leading Zeal Therapeutics, a precision kidney RNA therapeutics company. Check out the full episode: https://buildingbiotechspodcast.com/episode/49 ✔️Subscribe to our Mailing List for weekly podcast drops and industry news (we promise no spam!) https://buildingbiotechs.beehiiv.com/ Follow us on Apple, Spotify, or wherever you love to listen. 👉 https://apple.co/3EDuZvA 👉 https://spoti.fi/48bs3nq Stay connected with us: 🌐 Website: https://buildingbiotechspodcast.com/ 💼 LinkedIn: https://www.linkedin.com/company/building-biotechs-podcast/ 🎙️Check out our sister podcast, Biotech Career Coach: https://biotechcareercoach.com/ Follow and Connect with Carina on LinkedIn: https://www.linkedin.com/in/cclingman/ In need of Fractional Talent Acquisition or Recruiting help? Reach out! info@recruitomics.com

This week, I spoke with Natalie Nairn, co-founder and CEO of Cyclera Therapeutics. Natalie is also a Termeer Fellow, and listeners of this podcast know how much I love the Termeer Foundation. We discuss her transition from chemical engineering to biomedical applications. She describes her unexpected path into the fun and volatile startup space, which led to her founding Cyclera. Natalie explains the importance of focusing in biotech development, the promising applications of Cyclera's technology in CNS therapeutics, and the challenges and opportunities in the current funding landscape. She also highlights the value of the Termeer fellowship in her career, the contrast between Boston and Seattle's biotech scenes, and the essential aspects of leadership and team cohesion. Finally, Natalie discusses her future goals for Cyclera and offers valuable advice for aspiring biotech founders. Check out the full episode: https://buildingbiotechspodcast.com/episode/52 ✔️Subscribe to our Mailing List for weekly podcast drops and industry news (we promise no spam!) https://buildingbiotechs.beehiiv.com/ Follow us on Apple, Spotify, or wherever you love to listen. 👉 https://apple.co/3EDuZvA 👉 https://spoti.fi/48bs3nq Stay connected with us: 🌐 Website: https://buildingbiotechspodcast.com/ 💼 LinkedIn: https://www.linkedin.com/company/building-biotechs-podcast/ 🎙️Check out our sister podcast, Biotech Career Coach: https://biotechcareercoach.com/ Follow and Connect with Carina on LinkedIn: https://www.linkedin.com/in/cclingman/ In need of Fractional Talent Acquisition or Recruiting help? Reach out! info@recruitomics.com

In this episode, I had an engaging conversation with Stacie Frye, Co-Founder and Chief Commercial Officer of StimulusBio, a life sciences commercialization and venture studio for biotech startups. We discussed how StimulusBio aids startups in operational and commercialization aspects, leveraging Stacie's unique journey across marketing, chemical engineering, and her experience with successful biotech exits. Experience from previous startups profoundly informs StimulusBio’s approach to helping startups transition from incubation to market. We explored the critical stages of startup growth, emphasizing the importance of marketing, storytelling, team building, and experience-based advice. Stacie also shared her insights into the emerging trends in the biotech industry, particularly in Houston's growing biotech ecosystem, and the importance of balancing innovation with practical business needs. Check out the full episode: https://buildingbiotechspodcast.com/episode/51 ✔️Subscribe to our Mailing List for weekly podcast drops and industry news (we promise no spam!) https://buildingbiotechs.beehiiv.com/ Follow us on Apple, Spotify, or wherever you love to listen. 👉 https://apple.co/3EDuZvA 👉 https://spoti.fi/48bs3nq Stay connected with us: 🌐 Website: https://buildingbiotechspodcast.com/ 💼 LinkedIn: https://www.linkedin.com/company/building-biotechs-podcast/ 🎙️Check out our sister podcast, Biotech Career Coach: https://biotechcareercoach.com/ Follow and Connect with Carina on LinkedIn: https://www.linkedin.com/in/cclingman/ In need of Fractional Talent Acquisition or Recruiting help? Reach out! info@recruitomics.com

This week I had a great conversation with Russ Peloquin, Managing Partner of LifeSci Catalyst Partners. We dive into Russ's unique journey from aspiring exterminator (yes, you read that right!) to leading life science entrepreneur, discussing his extensive experience in commercialization, mergers, and acquisitions. Russ shares invaluable insights on the importance of marketing, fundraising strategies for biotech startups, the phases of taking a company from idea to commercialization, and the critical steps toward securing regulatory approvals. We also touch on the intersection of genome sequencing, blockchain, and AI, exploring how this convergence is set to democratize and capitalize on personal DNA. Whether you're new to biotech or an industry veteran, this episode offers a wealth of knowledge and practical advice on navigating the complex landscape of life sciences and startups. Check out the full episode: https://buildingbiotechspodcast.com/episode/54/ ✔️Subscribe to our Mailing List for weekly podcast drops and industry news (we promise no spam!) https://buildingbiotechs.beehiiv.com/ Follow us on Apple, Spotify, or wherever you love to listen. 👉 https://apple.co/3EDuZvA 👉 https://spoti.fi/48bs3nq Stay connected with us: 🌐 Website: https://buildingbiotechspodcast.com/ 💼 LinkedIn: https://www.linkedin.com/company/building-biotechs-podcast/ 🎙️Check out our sister podcast, Biotech Career Coach: https://biotechcareercoach.com/ Follow and Connect with Carina on LinkedIn: https://www.linkedin.com/in/cclingman/ In need of Fractional Talent Acquisition or Recruiting help? Reach out! info@recruitomics.com

This week, I had an insightful conversation with David Sans, PhD, FAARM, MBA, who heads healthcare investment banking at EF Hutton. We discussed the intricacies of different Public Offering strategies, including micro IPOs, which offer a unique avenue for biotech companies. David provides a deep perspective on the strategic implications of IPOs for biotech funding. He emphasized the importance of investor support and strategic banking partnerships, especially for micro IPOs. We also discussed the potential of AI in reshaping financial services and the future of outcome-based pricing models in investment. David's personal insights reveal the demanding yet rewarding nature of investment banking and highlight crucial aspects to consider for those pursuing a career in this field. Check out the full episode: https://buildingbiotechspodcast.com/episode/50 ✔️Subscribe to our Mailing List for weekly podcast drops and industry news (we promise no spam!) https://buildingbiotechs.beehiiv.com/ Follow us on Apple, Spotify, or wherever you love to listen. 👉 https://apple.co/3EDuZvA 👉 https://spoti.fi/48bs3nq Stay connected with us: 🌐 Website: https://buildingbiotechspodcast.com/ 💼 LinkedIn: https://www.linkedin.com/company/building-biotechs-podcast/ 🎙️Check out our sister podcast, Biotech Career Coach: https://biotechcareercoach.com/ Follow and Connect with Carina on LinkedIn: https://www.linkedin.com/in/cclingman/ In need of Fractional Talent Acquisition or Recruiting help? Reach out! info@recruitomics.com

This week I had a fun conversation with Jason Cordiero, Chief Operating and Innovation Officer at MassBio. We dissect MassBio's newly announced five-year strategic plan that includes a multi-pronged set of initiatives aimed at advancing the biotech industry. From supporting early-stage startups to advocating for policy changes and fostering talent development, Jason details the excellent resources available and in development. Whether you're based in Massachusetts or global, this session provides valuable information on how MassBio is working to catalyze innovation and growth in biotech, and how you can leverage these opportunities. Check out the full episode: https://buildingbiotechspodcast.com/episode/48 ✔️Subscribe to our Mailing List for weekly podcast drops and industry news (we promise no spam!) https://buildingbiotechs.beehiiv.com/ Follow us on Apple, Spotify, or wherever you love to listen. 👉 https://apple.co/3EDuZvA 👉 https://spoti.fi/48bs3nq Stay connected with us: 🌐 Website: https://buildingbiotechspodcast.com/ 💼 LinkedIn: https://www.linkedin.com/company/building-biotechs-podcast/ 🎙️Check out our sister podcast, Biotech Career Coach: https://biotechcareercoach.com/ Follow and Connect with Carina on LinkedIn: https://www.linkedin.com/in/cclingman/ In need of Fractional Talent Acquisition or Recruiting help? Reach out! info@recruitomics.com

This week I had a great conversation with Iva Toudjarska, founder and CEO of Zeal Therapeutics. From earning a PhD in molecular biology to a solid scientific career at Alnylam, to working in venture capital, to selling a successful SaaS company, Iva’s career that’s set her up well to enjoy this new challenge – founding a baby biotech. Her expertise marries business development, venture capital, and company-building. Iva shared valuable advice for biotech founders on securing funding, making strategic decisions, and building effective partnerships. Tune in to hear her experiences, lessons learned, and her current work leading Zeal Therapeutics, a precision kidney RNA therapeutics company. Check out the full episode: https://buildingbiotechspodcast.com/episode/49 ✔️Subscribe to our Mailing List for weekly podcast drops and industry news (we promise no spam!) https://buildingbiotechs.beehiiv.com/ Follow us on Apple, Spotify, or wherever you love to listen. 👉 https://apple.co/3EDuZvA 👉 https://spoti.fi/48bs3nq Stay connected with us: 🌐 Website: https://buildingbiotechspodcast.com/ 💼 LinkedIn: https://www.linkedin.com/company/building-biotechs-podcast/ 🎙️Check out our sister podcast, Biotech Career Coach: https://biotechcareercoach.com/ Follow and Connect with Carina on LinkedIn: https://www.linkedin.com/in/cclingman/ In need of Fractional Talent Acquisition or Recruiting help? Reach out! info@recruitomics.com